These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7654429)

  • 61. Docetaxel in combination with dacarbazine in patients with advanced melanoma.
    Bafaloukos D; Aravantinos G; Fountzilas G; Stathopoulos G; Gogas H; Samonis G; Briasoulis E; Mylonakis N; Skarlos DV; Kosmidis P
    Oncology; 2002; 63(4):333-7. PubMed ID: 12417787
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
    Sternberg CN; ten Bokkel Huinink WW; Smyth JF; Bruntsch V; Dirix LY; Pavlidis NA; Franklin H; Wanders S; Le Bail N; Kaye SB
    Br J Cancer; 1994 Aug; 70(2):376-9. PubMed ID: 7914427
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Docetaxel in the treatment of ovarian cancer.
    Kavanagh JJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Docetaxel for previously treated non-small-cell lung cancer.
    Fossella FV
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):45-51. PubMed ID: 12108897
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent breast cancer].
    Taguchi T; Mori S; Abe R; Hasegawa K; Morishita Y; Tabei T; Sasaki Y; Fujita M; Enomoto K; Hamano K
    Gan To Kagaku Ryoho; 1994 Nov; 21(15):2625-32. PubMed ID: 7979423
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
    Francis PA; Rigas JR; Kris MG; Pisters KM; Orazem JP; Woolley KJ; Heelan RT
    J Clin Oncol; 1994 Jun; 12(6):1232-7. PubMed ID: 7911159
    [TBL] [Abstract][Full Text] [Related]  

  • 68. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
    Georgoulias V; Androulakis N; Dimopoulos AM; Kourousis C; Kakolyris S; Papadakis E; Apostolopoulou F; Papadimitriou C; Vossos A; Agelidou M; Heras P; Tzannes S; Vlachonicolis J; Mavromanolakis E; Hatzidaki D
    Ann Oncol; 1998 Mar; 9(3):331-4. PubMed ID: 9602269
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
    Picus J; Schultz M
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):14-8. PubMed ID: 10604263
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The taxoids. Comparative clinical pharmacology and therapeutic potential.
    Eisenhauer EA; Vermorken JB
    Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Coping with toxicities of docetaxel (Taxotere).
    Schrijvers D; Wanders J; Dirix L; Prove A; Vonck I; van Oosterom A; Kaye S
    Ann Oncol; 1993 Aug; 4(7):610-1. PubMed ID: 8103352
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Paclitaxel hypersensitivity reactions: a role for docetaxel substitution.
    Lokich J; Anderson N
    Ann Oncol; 1998 May; 9(5):573. PubMed ID: 9653501
    [No Abstract]   [Full Text] [Related]  

  • 74. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia.
    Lemenager M; Lecomte S; Bonneterre ME; Bessa E; Dauba J; Bonneterre J
    Eur J Cancer; 1997 Feb; 33(2):297-300. PubMed ID: 9135504
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical characteristics of severe peripheral neuropathy induced by docetaxel (Taxotere).
    Hilkens PH; Verweij J; Vecht CJ; Stoter G; van den Bent MJ
    Ann Oncol; 1997 Feb; 8(2):187-90. PubMed ID: 9093729
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A phase II study of taxol in patients with malignant melanoma.
    Einzig AI; Hochster H; Wiernik PH; Trump DL; Dutcher JP; Garowski E; Sasloff J; Smith TJ
    Invest New Drugs; 1991 Feb; 9(1):59-64. PubMed ID: 1673965
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions.
    Briasoulis E; Karavasilis V; Pavlidis N
    Ann Oncol; 2000 Jul; 11(7):899. PubMed ID: 10997824
    [No Abstract]   [Full Text] [Related]  

  • 78. A Phase II study of Bruceantin (NSC-165, 563) in advanced malignant melanoma.
    Arseneau JC; Wolter JM; Kuperminc M; Ruckdeschel JC
    Invest New Drugs; 1983; 1(3):239-42. PubMed ID: 6678872
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.
    Alberto P; Rozencweig M; Clavel M; Siegenthaler P; Cavalli F; Gundersen S; Bruntsch U; Renard J; Pinedo H
    Cancer Chemother Pharmacol; 1986; 16(1):78-9. PubMed ID: 2933177
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Exploratory use of docetaxel loaded acid-prepared mesoporous spheres for the treatment of malignant melanoma.
    Kaiser S; MacPherson MB; James TA; Emery A; Spiess P; van der Vliet A; Landry CC; Shukla A
    Cancer Nanotechnol; 2015; 6(1):1. PubMed ID: 25642297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.